TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04265807

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
Study: NCT00670280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing intervention
Description: Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
Study: NCT01537172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4053
Description: Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
Study: NCT00670280

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
Study: NCT01537172

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
Study: NCT02634177

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Assay-guided treatment (AGT)
Description: The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment-as-usual (TAU)
Description: Subjects are treated-as-usual without the aid of the assay.
Study: NCT00670280

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care - Reduced Measurement
Description: Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
Study: NCT00300755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole sodium enteric-coated spheroid
Description: pediatric spheroids taken daily x 8 weeks
Study: NCT00700427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atomoxetine hydrochloride
Description: Oral 40-100 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral delivery of matching placebo
Study: NCT03711331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FilmArray® Pneumonia panel plus
Description: Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
Study: NCT03711331

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
Study: NCT02067559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICU Diary
Description: Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
Study: NCT01303484

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bi2muno® GOS
Description: 5.5g/day for 10 weeks
Study: NCT01936675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Risk Score
Description: Patients in this arm will receive their genetic-informed risk for having a heart attack.
Study: NCT03228771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRGF/ATV
Description: Atorvastatin loaded in PRGF fibrin scaffold

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV gel
Description: Atorvastatin loaded in methyl cellulose gel
Study: NCT03493295

Intervention type: DRUG
Intervention: Levonogestrel IntraUterine System (LNG-IUS)
Description: At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
Study: NCT02719496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBEROGAST
Study: NCT02067559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICU Diary
Description: Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
Study: NCT03073239

Intervention type: GENETIC
Intervention: ALS patients genetic characterization
Description: Genetic findings in ALS patients

Intervention type: OTHER
Intervention: ALS patients epidemiological caracterization
Description: Epidemiological characterization in ALS patients
Study: NCT01867736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DRB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA (POBA)
Study: NCT04561895

Intervention type: GENETIC
Intervention: DNA extraction
Description: investigation of DNA polymorphism in patients suffering from NAFLD

Intervention type: GENETIC
Intervention: DNA extraction
Description: investigation of DNA polymorphism in patients suffering from NAFLD
Study: NCT01556451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Live
Description: Zoster vaccine live
Study: NCT03030001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 antibody expressing mesothelin specific CAR-T cells
Description: Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
Study: NCT01729299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Study: NCT04357444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: ILT101
Description: Subcutaneous injections, once-daily administration for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2: Placebo Comparator
Description: placebo in Subcutaneous route
Study: NCT02625051

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy
Description: Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
Study: NCT03543657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Molidustat (BAY85-3934)
Description: Matching placebo of Molidustat.
Study: NCT01729299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyl ghrelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyl ghrelin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT02486536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Study: NCT03543657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Darbepoetin alfa
Description: Matching placebo of Darbepoetin alfa.
Study: NCT01792050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
Study: NCT05333952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary vein isolation
Description: The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
Study: NCT02486536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: capsule endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: capsule endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: capsule endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: capsule endoscopy
Study: NCT05333952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Substrate ablation(PRISM based)
Description: Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
Study: NCT01770106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70mg once weekly
Study: NCT02486536

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: capsule endoscopy
Study: NCT01459484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifamurtide arm
Description: PRE SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~All the product are used as commercial formulation
Study: NCT03520543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]Yohimbine
Description: Each subject will receive an intravenous (IV) bolus injection of \[11C\]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of \[11C\]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of \[11C\]Yohimbine.
Study: NCT01459484

Intervention type: OTHER
Group type: OTHER
Intervention: 3 drugs arm
Description: High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen~PRE-SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total lenght 34 weeks~All the product are used as commercial formulation
Study: NCT03520543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)
Description: Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following \[11C\]Yohimbine PET scan (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after \[11C\]Yohimbine PET scan of part A.~Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of \[11C\]Yohimbine (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of \[11C\]Yohimbine obtained at baseline (part A).
Study: NCT02029872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate soap
Description: 4% chlorhexidine gluconate (soap)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate soap
Description: 4% chlorhexidine gluconate (soap)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate oral rinse
Description: chlorhexidine gluconate oral rinse 0.12%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate oral rinse
Description: chlorhexidine gluconate oral rinse 0.12%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin calcium 2 % ointment
Description: nasal mupirocin calcium 2% ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin calcium 2 % ointment
Description: nasal mupirocin calcium 2% ointment
Study: NCT01579227

Intervention type: DEVICE
Intervention: Topical Tocotrienol (TCT)
Description: Natural Form Vitamin E topical cream(TCT)
Study: NCT02384265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IM/SMS + Incentive Condition
Description: See description of Intervention arm protocols above.
Study: NCT03951506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal exercise program
Description: Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
Study: NCT04480138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-α2b
Description: 1 mcg/kg on day 1 and day 8 after safety evaluations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care as per local authority

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care as per local authority
Study: NCT01303484

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 5.5g daily for 10 weeks
Study: NCT00718601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat Sodium (GRN163L)
Description: 25% dose escalation infused over 2 hours weekly
Study: NCT02188160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121
Description: KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study: NCT04432480

Intervention type: PROCEDURE
Intervention: NIPE (Newborn Infant Parasympathetic Evaluation) monitoring
Description: Non invasive monitor connected to standard anesthesia monitor (no part of the device in contact with the patient) during anesthesia.
Study: NCT01474343

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SAF-301
Description: The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
Study: NCT03440320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MY-SKILLS - online
Description: Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of yoga and an hour of self-management designed to meet the needs of a caregiving dyad with chronic pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MY-Plan control - online
Description: Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain..